Compare REGN & ECL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | ECL |
|---|---|---|
| Founded | 1988 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 77.5B |
| IPO Year | 1991 | N/A |
| Metric | REGN | ECL |
|---|---|---|
| Price | $769.28 | $284.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $802.36 | $295.00 |
| AVG Volume (30 Days) | 812.3K | ★ 1.1M |
| Earning Date | 01-30-2026 | 02-10-2026 |
| Dividend Yield | 0.46% | ★ 1.03% |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 41.59 | 6.95 |
| Revenue | $14,247,800,000.00 | ★ $15,890,400,000.00 |
| Revenue This Year | $2.08 | $3.04 |
| Revenue Next Year | $6.82 | $6.03 |
| P/E Ratio | ★ $18.34 | $40.82 |
| Revenue Growth | ★ 2.89 | 1.38 |
| 52 Week Low | $476.49 | $221.62 |
| 52 Week High | $821.11 | $286.04 |
| Indicator | REGN | ECL |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 67.06 |
| Support Level | $747.30 | $271.22 |
| Resistance Level | $765.00 | $282.47 |
| Average True Range (ATR) | 21.66 | 4.36 |
| MACD | -2.54 | 1.03 |
| Stochastic Oscillator | 47.24 | 88.09 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.